Cancer-associated fibroblasts in hepatocellular carcinoma

Norio Kubo, Kenichiro Araki, Hiroyuki Kuwano, Ken Shirabe

Abstract

The hepatic stellate cells in the liver are stimulated sustainably by chronic injury of the hepatocytes, activating myofibroblasts, which produce abundant collagen. Myofibroblasts are the major source of extracellular proteins during fibrogenesis, and may directly, or secreted products, contribute to carcinogenesis and tumor progression. Cancer-associated fibroblasts (CAFs) are one of the components of the tumor microenvironment that promote the proliferation and invasion of cancer cells by secreting various growth factors and cytokines. CAFs crosstalk with cancer cells stimulates tumor progression by creating a favorable microenvironment for progression, invasion, and metastasis through the epithelial-mesenchymal transition. Basic studies on CAFs have advanced, and the role of CAFs in tumors has been elucidated. In particular, for hepatocellular carcinoma, carcinogenesis from cirrhosis is a known fact, and participation of CAFs in carcinogenesis is supported. In this review, we discuss the current literature on the role of CAFs and CAF-related signaling in carcinogenesis, crosstalk with cancer cells, immunosuppressive effects, angiogenesis, therapeutic targets, and resistance to chemotherapy. The role of CAFs is important in cancer initiation and progression. CAF-targeted therapy may be effective for suppression not only of fibrosis but also cancer progression.

Key words: Cancer associated fibroblast; Hepatic stellate cell; Hepatocellular carcinoma; Immunosuppression; Therapeutic target

© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Cancer-associated fibroblasts (CAFs) are one of the most crucial components of the tumor microenvironment that promote the carcinogenesis, proliferation and invasion of cancer cells by secreting various growth factors and cytokines. In hepatocellular carcinoma, involvement of CAFs in carcinogenesis is supported. In this review, we discuss the role of CAFs in cancer progression, and the role of CAF-targeted therapy for suppression of cancer progression.
Collagen 11A1 expression is a remarkable biomarker of a genetic change that affects surface markers. From cirrhotic tissue, may have already undergone (HSC) already occurred in activated hepatic stellate cells that DNA-methylation-based epigenetic changes have in CAFs compared to NTFs is evident, but mRNA expression of difference between CAFs and NTFs in surface markers can be detected by flow cytometry and immunofluorescence cells from cirrhotic tissue, can be detected by flow cytometry and immunofluorescence.

INTRODUCTION

Hepatocellular carcinoma (HCC) is the second most common cause of death from cancer worldwide, and accounted for nearly 746000 deaths in 2012[1]. Malignant tumors comprise cancer cells and stromal cells. For a long time, the malignant potential of the tumor was thought to be entirely due to the cancer cells because the stromal cells were not undergoing differentiation or activate proliferation[2]. Stromal cells were considered to simply surround the cancer cells and have a non-malignant function. Recent studies have clarified the origins, features, and roles of the stromal cells.

Fibroblasts in cancer tissues are similar in morphology to the myofibroblasts that are activated during the wound healing process[3]. Recent studies have shown the importance of cross talk between cancer cells and the fibroblasts called cancer-associated fibroblasts (CAFs)[4]. CAFs are active in a wound healing process similar to normal myofibroblasts[5], and promote tumor proliferation, invasion, and metastasis via secretion of various growth factors, cytokines and degradation of extracellular matrix proteins[6-8] (Figure 1).

CAFs are large spindle-shaped mesenchymal cells with positive immunostaining for vimentin, alpha smooth muscle actin, and developed fibronexus[9,10]. The types of surface marker proteins on CAFs and non-tumoral fibroblasts (NTFs), which are primary cells from cirrhotic tissue, can be detected by flow cytometry and immunofluorescence[4]. No significant difference between CAFs and NTFs in surface markers is evident, but mRNA expression of αSMA is higher in CAFs compared to NTFs[4]. It has been reported that DNA-methylation-based epigenetic changes have already occurred in activated hepatic stellate cells (HSC)[11,12]. Therefore, NTF, which are activated HSCs from cirrhotic tissue, may have already undergone a genetic change that affects surface markers. Collagen 11A1 expression is a remarkable biomarker of human carcinoma-associated stromal cells[13]. It was reported that even without exposure to cancer cells, the tumor promoting characteristics of CAFs can be stably maintained[14]. There remains a persistent risk for HCC in patients with advanced fibrosis who have achieved a sustained virologic response (SVR)[15]. Furthermore, activated HSCs can be stimulated by cancer cells, which then become CAFs. Details of differentiation into quiescent HSCs, HSCs, and CAFs is shown in the Table 1. Quiescent HSCs were characterized by the stored vitamin A with fat droplets[16] and are derived from the mesoderm[17]. HSCs have a function in wound healing and fibroblast production. Characterization of CAFs revealed that they were affected by cancer cells through “crossstalk”.

CARCINOGENESIS

It is well established in other systems that complex intercellular signaling networks exist between tumors and CAFs, contributing to cancer initiation, growth, and progression[18-22]. Tumor secretion of cytokines, such as transforming growth factor-β (TGF-β), stimulate myofibroblast activation leading to profound changes in extracellular matrix composition and organization. The role of mesenchymal stroma alterations in cancer initiation was proposed in the context of colon[23] and prostate[24] cancers. Chronic liver injuries caused by viral hepatitis, autoimmune hepatitis, alcoholic hepatitis, and non-alcoholic steatohepatitis activate and transform quiescent fibroblasts into activated myofibroblasts through the actions of increased growth factors and continued expression of inflammatory cytokines such as PDGF, TGF-β, TNF-α, IL-6, and IL-1β[25,26]. Fibroblasts might be directly activated by hepatitis C infection, which leads to production of reactive oxygen species and TGF-β[27]. The activated fibroblasts produce massive amounts of extracellular matrix proteins, including type I collagen, which leads to liver fibrosis[28]. Persistent inflammation in chronic hepatitis plays a major role in the development of HCC[29-31]. There remains a persistent risk for HCC in patients with advanced fibrosis who have achieved SVR[15]. Around 90% of HCC cases are associated with fibrotic or cirrhotic livers[32,33].

Dotto[34] suggested that while changes in tumor stroma are frequently viewed as secondary to changes in the epithelium, recent evidence indicates that they can play a primary role in both cancer progression and initiation. These changes include epigenetic events such as loss of p53[35-37]. These processes may explain the phenomenon of field cancerization, namely the occurrence of multifocal and recurrent epithelial tumors that are preceded by and associated with widespread changes of surrounding tissue or organ fields[34]. It thought that epigenetic changes affect CAFs in HSCs in cases of liver cirrhosis that include...
abundant fibrosis. However, gene analysis is not performed often enough in human HSCs of the liver cirrhosis or CAFs.

### CROSSTALK BETWEEN CANCER-ASSOCIATED FIBROBLASTS AND HCC CELLS
Recent studies have shown the importance of crosstalk between cancer cells and their stromal microenvironment, including HCCs and CAFs. CAFs are the most important cell type in the stroma and play a critical role in modulating neighboring cancer cells. CAFs stimulate malignant cell proliferation by providing different types of growth factors and cytokines in a context-dependent manner such as SDF-1, HGF, PDGF, TGF-β, IL-6, and EGF. When HCC cells are co-cultured with CAFs, CAFs induced by TIMP-1 repress HCC apoptosis with an increased Bcl-2/BAX ratio through SDF-1/CXCR4/PI3K/AKT signaling. Moreover, CAFs upregulated gene expressions of TGF-β and FAP, whereas NTFs did not induce the expression of either gene. HGF is expressed by CAFs, HSCs, and myofibroblasts, and it is a highly potent hepatocyte growth factor regulating cell proliferation, migration, survival, and angiogenesis. IL-6 stimulated progranulin...
expression contributes to the malignancy of HCC cells by activating mTOR signaling. After the IL-6/STAT3 pathway is activated, malignant cells proliferate much faster and their anti-apoptosis ability increases significantly. TGF-β complex is secreted by most cell types, including human HSCs and hepatocytes. TGF-β signaling promotes HCC progression by two mechanisms: first, via an intrinsic activity as an autocrine or paracrine growth factor; and second, via an extrinsic activity by inducing microenvironment changes, including CAFs activation, T regulatory cell increases, and inflammatory mediators. A recent study using transgenic mice suggested that PDGF-C overexpressing hepatocytes causes activation of HSC, which in turn produces HGF and cytokines, resulting in the development of HCC. Crosstalk between TGF-β and PDGF signaling supports epithelial mesenchymal transition (EMT), which is crucial for tumor growth and the acquisition of an invasive phenotype. MRC-5 fibroblast-conditioned medium influences multiple pathways regulating invasion in HCC.

Lysophosphatidic acid (LPA) is a lipid mediator that is involved in multiple cellular events associated with tumor initiation and progression, invasion, and metastasis. LPA is secreted by HCC cells and promotes transdifferentiation of myofibroblasts by the paracrine mechanism and has been clearly shown to be a therapeutic target for tumor-CAF interactions in HCC. MMP-9 is downstream of LPA and has been postulated to have a critical role in HCC cell invasion and metastasis by secreting various matrix-degrading proteases as well as their activators such as uPA.

These functions of CAFs in supporting HCC growth were confirmed by in vitro experiments involving co-culture of HCC cell lines with CAFs. Remarkably, the activation of CAFs was maintained after their isolation from cells of various cancer types such as squamous skin carcinoma, lung carcinoma, breast carcinoma, and scirrhous gastric cancer. Exposure to leukemia inhibitory factor initiates an epigenetic switch causing the constitutive activation of JAK1/STAT3 signaling, which results in sustained activation of CAFs. DNA methylation plays critical roles in the control of sustained and constitutive activation of signaling pathways. CAF activation is accompanied by stromal cell senescence. Concomitant loss of CSL (also known as RBP-Jk) and p53 overcomes fibroblast senescence, enhances expression of CAF effectors, and promotes stromal and cancer cell expansion through β-galactosidase, IL-6, and IL-8 respectively. Xenografts in nude mice also demonstrated in vivo tumor growth enhancement by CAFs.

Immunosuppression by CAFs

There is an impaired anti-tumor response within the HCC microenvironment due to various immune suppressive elements, including regulatory T cells (Tregs), tumor-associated macrophages (TAMs), and tumor-associated neutrophils (TANs). Among the immune cell types present within the HCC, TAMs play a leading role in the setting of the crosstalk between tumor and stromal cells. TAMs are mainly polarized towards an M2 phenotype, which is a major component of leukocyte infiltration of tumors and plays a pivotal role in tumor progression of HCC. Increased TAMs are correlated with angiogenesis, metastasis, and poor prognosis. STAT3 activation is correlated with aggressive behavior of HCC and may be mediated via TAMs.

CAFs educate NK cells to acquire a deactivated phenotype and create an unresponsive condition in tumors. This suppression is eliminated by indoleamine 2,3-dioxygenase (IDO) and/or PGE2 inhibitors. CAFs recruit regulatory dendritic cells and educate them to acquire a tolerogenic phenotype through IL-6 mediated STAT3 activation and upregulate the production of Tregs by secreting TGF-β in tumor microenvironments. The mechanisms underlying CAFs’ immunomodulatory effects in HCC may be mediated via upregulation of human B7 homolog 1 (B7-H1) in CAFs. B7-H1/programmed death 1 (PD-1) signaling promotes Treg cell induction and immunosuppressive function through the down regulation of mTOR and AKT phosphorylation. Using these immunosuppression effects, CAFs that receive cytokine signals from cancer cells produce an environment that is convenient for cancer cells.

ANGIOGENESIS

A hypoxic condition activates Akt, which increases the expression of vascular endothelial growth factor (VEGF), the most important angiogenic factor. The rapid growth of the HCC requires new vessels. CAFs secrete angiogenic factors, including VEGF, PDGFs, MMPs, FGF, TGF-β1, EGF, angiopoietin-1, and angiopoietin-2, which have a critical role in HCC initiation, progression, and metastasis, and creates new vessels. VEGF receptor, PDGF receptor, and Tie-2 upregulation also occur during CAFs activation, resulting in increased mitogenesis in response to VEGF. VEGF secretion by HSCs can be hormonally induced by leptin, or by physical stress such as hypoxia, and is upregulated in HCC. Conditioned medium from HCC cells can activate CAFs and stimulate VEGF production. Oxidative stress enhances the malignant potential of HCC through the stimulation of angiogenesis by activation of the Akt-VEGF pathway. Angiogenesis is also facilitated by TAM-derived proteases because extracellular proteolysis is necessary for new vessel formation. The most prominent proteases that promote tumor-directed angiogenesis include matrix metalloproteinase, plasmin, and urokinase-type plasminogen activator and its receptor.
CAFS AS THERAPEUTIC TARGETS IN HCC

Anti-cancer therapy targeting CAFs or inhibitors of the cytokines secreted by CAFs has been actively investigated recently. Inhibitors of TGF-β signaling have been shown to block HCC growth and progression by modulating EMT in different experimental models, leading to the clinical investigation of a TGF-β inhibitor monohydrate in HCC[68]. Several receptor tyrosine kinase inhibitors target VEGF and PDGF. Linifanib is a potent inhibitor of VEGF, PDGF, PDGFR-β, KDR, and colony stimulating factor-1-receptor (CSF). Sunitinib inhibits receptors for PDGF and VEGF, as well as other receptor tyrosine kinases such as CSF. Some groups have explored active targeting of CAFs to deliver therapeutic compounds. This involves coupling the selected compound to a carrier possessing a specific receptor binding ligand or an antibody. Carriers employed have included an antibody to the synaptophysin receptor on CAFs, and a liposome specific to the vitamin A receptor on CAFs[68,113,114].

These therapeutic targets are several cytokines secreted by CAFs or signals from CAFs that stimulate the HCC. Liver fibrosis is treated with anti-fibrotic drugs that inhibit the activation of quiescent HSCs and promote cell death in activated HSC. If CAFs are an activated state of HSC, it is possible that these drugs were effective for CAFs. A recent report suggested some anti-fibrotic drugs, such as PRI-724[115], conophylline[116], arnemapavine[117], follistatin[118], salvianolic acids[119], ursolic acid[120], giotoxin[121], curcumin[122], sulfurasalazine[123], benzodiazepine[124] and tanshinone I[125], which suppress activated HSCs and/or induce apoptosis. It is thought that these drugs not only control the fibrosis, but also suppress the HCC by controlling the function of CAFs. Restraining fibrosis may lead to controlling further carcinogenesis according to the theories about field cancerization.

Fibrolamellar HCC was surrounded by laminated fibrous stroma[126]. It was reported the overexpression of fibroblast growth factor receptor 1 in fibrolamellar HCC[127]. CAFs stimulate tumor cells by FGFR[50,51] and produced fibrosis. Treatment targeting CAFs might be effective in a fibrolamellar HCC.

CAFS stimulate malignant cell proliferation by providing different types of growth factors and cytokines in a context-dependent manner[128] such as SDF-1[129,130], HGF[129-131], members of the epidermal growth factor family[132], fibroblast growth factor (FGF)[50,51].

CHEMoresistance

After undergoing EMT, malignant cells become more resistant to chemotherapy, and those expressing surface molecules of stem cells increase, suggesting a close link between CAF-induced EMT, tumor stem cells, and chemoresistance of tumor cells[128,129]. miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts[130]. Tumors with stromal phenotypes are more chemoresistant and share more characteristics with tumor stem cells[131]. CAFs are primarily resistant to chemotherapy due to a small proportion of proliferating cells in contrast to malignant cells[132]. CAFs induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells[133]. CAFs attenuate the sensitivity to cisplatin in ovarian cancer cells by promoting STAT3 signaling[134]. These findings about a connection between CAFs and chemoresistance are from recent studies, and the mechanisms of resistance are still unclear.

CONCLUSION

CAFs are one of the most crucial components of the tumor microenvironment that promote the growth and invasion of cancer cells by various mechanisms. Chronic inflammation was previously considered the main reason for carcinogenesis leading to HCC. However, there remains a persistent risk for HCC in patients with advanced fibrosis who have achieved SVR[135]. These results suggest that procarcer stromal alterations were made by the CAFs and CAFs related cells. In conclusion, CAFs are important for cancer cell initiation and progression, and therapy targeting CAFs may be effective for treating fibrosis and preventing HCC progression.

REFERENCES

1. Thompson AI, Conroy KP, Henderson NC. Hepatic stellate cells: central modulators of hepatic carcinogenesis. BMC Gastroenterol 2015; 15: 63 [PMID: 26011323 DOI: 10.1186/s12876-015-0291-5]
2. Shiga K, Hara M, Nagaoka T, Sato T, Takahashi H, Takeyama H. Cancer‐Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth. Cancers (Basel) 2015; 7: 2443-2458 [PMID: 26690480 DOI: 10.3390/cancers7040902]
3. De Wever O, Demetter P, Mareel M, Bracke M. Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 2008; 123: 2229-2238 [PMID: 18777559 DOI: 10.1002/ijc.23925]
4. Sukowati CH, Anfuso B, Croce LS, Tirimelli C. The role of multipotent cancer associated fibroblasts in hepatocarcinogenesis. BMC Cancer 2015; 15: 188 [PMID: 25879842 DOI: 10.1186/s12885-015-0961-8]
5. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002; 3: 349-363 [PMID: 11988769 DOI: 10.1038/nrm809]
6. Terada T, Makimoto K, Terayama N, Suzuki Y, Nakanuma Y. Alpha-smooth muscle actin-positive stromal cells in cholangiocarcinomas, hepatocellular carcinomas and metastatic liver carcinomas. J Hepatol 1996; 24: 706-712 [PMID: 8835746]
7. Yamamura Y, Asai N, Enomoto A, Kato T, Miyata K, Kondo Y, Ushida K, Niimi K, Tsuoda N, Nagino M, Ichihara S, Furukawa K, Maeda K, Murohara T, Takahashi M. Akt-Girdin signaling in cancer-associated fibroblasts contributes to tumor progression. Cancer Res 2015; 75: 813-823 [PMID: 25732845 DOI: 10.1158/0008-5472.CAN-14-1317]
8. Song J, Ge Z, Yang X, Luo Q, Wang C, You H, Ge T, Deng Y, Lin H, Cui Y, Chu W, Yao M, Zhang Z, Gu J, Fan J, Qin W. Hepatic...
The myofibroblast: phenotypic characterization as a prerequisite to understanding its functions in translational medicine. J Cell Mol Med 2008; 12: 22-37 [PMID: 18128061 DOI: 10.1111/j.1582-4934.2007.00213.x]

De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol 2003; 200: 429-447 [PMID: 12845611 DOI: 10.1002/path.1398]

El Taghdoudia A, Sørensen AL, Reiner AH, Coll M, Verhulst K, Kinzler KW, Vogelstein B. Landscaping the cancer terrain. J Clin Invest 2014; 124: 1446-1453 [PMID: 24691479 DOI: 10.1172/JCI72589]

Braix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022 [PMID: 21374666 DOI: 10.1002/hep.24199]

Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-1255 [PMID: 22353262 DOI: 10.1016/S0140-6736(11)61347-0]

Dotto GP. Multifocal epithelial tumors and field cancerization: stroma as a primary determinant. J Clin Invest 2014; 124: 1446-1453 [PMID: 24691479 DOI: 10.1172/JCI72589]

Hu M, Yao J, Cai L, Bachman KE, van den Brule F, Velculescu V, Polyak K. Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet 2005; 37: 899-905 [PMID: 16007089 DOI: 10.1038/ng1596]

Jiang L, Gonda TA, Gambale MV, Salas M, Seshan V, Tu S, Twaddell WS, Haggii P, Lazar G, Steele I, Varro A, Wang TC, Tycko B. Global hypomethylation of genomic DNA in cancer-associated myofibroblasts. Cancer Res 2008; 68: 9900-9908 [PMID: 19047171 DOI: 10.1158/0008-5472.CAN-08-1319]

Hill R, Song Y, Cardiff RD, Van Dyke T. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 2005; 123: 1001-1011 [PMID: 16366003 DOI: 10.1016/j.cell.2005.09.030]

Lin ZY, Chung WL. Hepatocellular carcinoma cells cause different responses in expressions of cancer-promoting genes in different cancer-associated fibroblasts. Kaohsiung J Med Sci 2013; 29: 312-318 [PMID: 23684136 DOI: 10.1016/j.kjms.2012.08.012]

Kim GJ, Rhee H, Yoo JE, Ko JE, Lee JS, Kim H, Choi JS, Park YN. Increased expression of CCN2, epithelial membrane antigen, and fibroblast activation protein in hepatocellular carcinoma with fibrous stroma showing aggressive behavior. PLoS One 2014; 9: e105094 [PMID: 25126747 DOI: 10.1371/journal.pone.0105094]

Eiró N, Vizzoso FJ. Importance of tumor/stroma interactions in prognosis of hepatocellular carcinoma. Hepatobiliary Surg Nutr 2014; 3: 98-101 [PMID: 24812604 DOI: 10.3978/j.issn.2304-3881.2014.01.02.12]

Mazzocca A, Ditturi F, Lupó L, Quarranta M, Antonacci S, Giannelli G. Tumor-secreted lysophosphatic acid accelerates hepatocellular carcinoma progression by promoting differentiation of peritumoral fibroblasts in myofibroblasts. Hepatology 2011; 54: 920-930 [PMID: 21674557 DOI: 10.1002/hep.24485]

Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121: 335-348 [PMID: 15882617 DOI: 10.1016/j.cell.2005.02.034]

Zheng K, Li HY, Su XL, Wang XY, Tian T, Li F, Ren GS.
Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells. J Exp Clin Cancer Res 2010; 29: 31 [PMID: 20380740 DOI: 10.1186/1555-6012-29-31]

44 Song T, Dou C, Jia Y, Tu K, Zheng X. TIMP-1 activated carcinoma-associated fibroblasts inhibit tumor apoptosis by activating SDF1/CXCR4 signaling in hepatocellular carcinoma. Oncotarget 2015; 6: 12061-12079 [PMID: 25909286 DOI: 10.18632/oncotarget.6316]

45 Teng F, Tian WY, Wang YM, Zhang YF, Guo F, Zhao J, Gao C, Xue FX. Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis. J Hematol Oncol 2016; 9: 8 [PMID: 26851944 DOI: 10.1186/s13045-015-0231-4]

46 Amann T, Bataille F, Sprüss T, Mühlbauer M, Gäbele E, Schlömer J, Kiefer P, Srprzböck AK, Hellerbrand C. Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci 2009; 100: 646-653 [DOI: 10.1111/j.1349-7006.2009.01087.x]

47 Li Q, Wang W, Yamada T, Matsumoto K, Sakai K, Bando Y, Uehara H, Nishioka Y, Sone I, Iwaki S, Itori K, Utsugi T, Yasumoto K, Hano S. Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network. Am J Pathol 2011; 179: 1483-1493 [DOI: 10.1016/j.ajpath.2011.05.060]

48 Jia CC, Wang TT, Liu W, Fu BS, Hua X, Wang GY, Li T, Li X, Wu XY, Tai Y, Zhou J, Chen GH, Zhang Q. Cancer-associated fibroblasts from hepatocellular carcinoma promote malignant cell proliferation by HGF secretion. PLoS One 2013; 8: e63243 [PMID: 23667593 DOI: 10.1371/journal.pone.0063243]

49 Yan XL, Fu CJ, Chen L, Qin JH, Zeng Q, Yuan HF, Nan X, Chen CH, Zhou JN, Li YL, Zhang YM, Yu CZ, Yue W, Pei XT. Mesenchymal stem cells from primary breast cancer tissue contribute to cancer proliferation and enhance mammosphere formation partially via EGFR/EGFR/Akt pathway. Breast Cancer Res Treat 2012; 132: 153-164 [PMID: 21584665 DOI: 10.1007/s10549-011-1577-0]

50 Spaeth EL, Dembinski JL, Sassier AK, Watson K, Klopp A, Hall B, Andreesen M, Marin F. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 2009; 4: e4992 [PMID: 19352430 DOI: 10.1371/journal.pone.004992]

51 Giulianelli S, Ceriliani JP, Lamb CA, Fabris VT, Bottino MC, Gorostaga MA, Novaro V, Gongora A, Baldi A, Molinolo A, Lanari C. Carcinoma-associated fibroblasts activate progesterone receptors and induce hormone independent mammary tumor growth: A role for the RGF-2/FGFR-2 axis. Int J Cancer 2005; 123: 1558-1561 [PMID: 15760400 DOI: 10.1002/ijc.20781]

52 Fu L, Zhang C, Zhang LY, Dong SS, Lu LH, Chen J, Dai Y, Li Y, Kong KL, Kong W, Guan XY. Cancer-associated fibroblasts promote tumor progression in oesophageal cancer by activation of the Wnt/β-catenin signalling pathway. Cancer Sci 2009; 100: 646-653 [PMID: 19575660 DOI: 10.1111/j.1349-7006.2009.01087.x]

53 Liu J, Fu BS, Guo H, Ren Z, Zheng S, Zhou L. MRC-5 fibroblast-conditioned media stimulates ovarian carcinoma cell growth and tumor growth of human hepatocellular carcinoma cells. J Exp Clin Cancer Res 2010; 29: 31 [PMID: 20380740 DOI: 10.1186/1555-6012-29-31]

54 Paland N, Kamer J, Kogan-Sakin I, Madar S, Goldfinger N, Rotter V. Differential influence of normal and cancer-associated fibroblasts on the growth of human epithelial cells in an in vitro cocultivation model of prostate cancer. Mol Cancer Res 2009; 7: 1212-1223 [PMID: 19671672 DOI: 10.1158/1541-7786.MCR-09-0073]

55 Lin ZX, Zhang YH, Zhang WL. Cancer-associated fibroblasts up-regulate CCL2, CCL26, IL-6 and LOXL2 genes related to promotion of cancer progression in hepatocellular carcinoma cells. Biomed Pharmacother 2012; 66: 525-529 [PMID: 22739041 DOI: 10.1016/j.biopha.2012.02.001]

56 Liu F, Zhang W, Yang F, Feng T, Zhou M, Yu Y, Xu X, Zhao W, Yi F, Tang W, Lu Y. Interleukin-6-stimulated progranulin expression contributes to the malignancy of hepatocellular carcinoma cells by activating mTOR signaling. Sci Rep 2016; 6: 21260 [PMID: 26879559 DOI: 10.1038/srep21260]

57 Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392-401 [PMID: 16572188 DOI: 10.1038/nrc1877]

58 Xing F, Saidou J, Watabe K. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci (Landmark Ed) 2010; 15: 166-179 [PMID: 20036813]

59 Guirouilh J, Le Bail B, Bousarie L, Balabaad C, Bioulac-Sage P, Desmouliere A, Schuppan D, Rosenbaum J. Expression of hepatocyte growth factor in human hepatocellular carcinoma. J Hepatol 2001; 34: 78-83 [PMID: 11211911]

60 Efimova EA, Glanemann M, Liu L, Schumacher G, Settmacher U, Jonas S, Langrehr JM, Neuhaus P, Nässler AK. Effects of human hepatocyte growth factor on the proliferation of human hepatocytes and hepatocellular carcinoma cell lines. Eur Surg Res 2004; 36: 300-307 [PMID: 15359093 DOI: 10.1159/000079915]

61 Monvoisin A, Neaud V, De Ledénving V, Dubaussion L, Balabaad C, Bioulac-Sage P, Desmouliere A, Rosenbaum J. Direct evidence that hepatocyte growth factor-induced invasion of hepatocellular carcinoma cells is mediated by urokinase. J Hepatol 1999; 30: 511-518 [PMID: 10190737]

62 Suzuki A, Hayashida M, Kawano H, Sugimoto K, Nakano T, Shiraki K. Hepatocyte growth factor promotes cell survival from fas-mediated cell death in hepatocellular carcinoma cells via Akt activation and Fas-death-inducing signaling complex suppression. Hepatology 2000; 32: 796-802 [PMID: 11003625 DOI: 10.1053/jhep.2000.17738]

63 Schmidt C, Bladé F, Goedecke S, Brinkmann V, Zschiesche W, Sharpe M, Gherardi E, Birchmeier C. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 1995; 373: 699-702 [PMID: 7854452 DOI: 10.1038/373699a0]

64 Haura EB, Turkson J, Jove R. Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2005; 2: 315-324 [PMID: 16269989 DOI: 10.1038/ncponc0195]

65 Meyer DH, Bachem MG, Gressner AM. Modulation of hepatic lipoygenase cytochrome P-450 synthesis and proliferation by Kupffer cell-derived transforming growth factor-α and transforming growth factor-β as a therapeutic target in hepatocellular carcinoma. Cancer Res 2014; 74: 1890-1894 [PMID: 24638984 DOI: 10.1158/0008-5472.CAN-14-0243]

66 Wright JH, Johnson MM, Shimizu-Albergine M, Bauer RL, Hayes BJ, Surapisitchat J, Hudkins KL, DuBussion L, Balabaad C, Bioulac-Sage P, Desmouliere A, Rosenbaum J. Induction of hepatocellular carcinoma. J Exp Med 2014; 213: 2644-2654 [PMID: 20238376 DOI: 10.1101/0008-5472.CAN-14-0243]

67 van Zijl F, Mair M, Csizsar A, Schnellner D, Zalehner G, Haber H, Eftekhari S, Breguet H, Dolszyn H, Mikułis W. Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge. Oncogene 2009; 28: 4022-4033 [PMID: 19718050 DOI: 10.1038/onc.2009.253]

68 Ding S, Chen G, Zhang W, Xing C, Xu X, Xie H, Lu A, Chen K, Guo H, Ren Z, Zheng S, Zhou L. MRC-5 fibroblast-conditioned
medium influences multiple pathways regulating invasion, migration, proliferation, and apoptosis in hepatocellular carcinoma. J Transl Med 2015; 13: 237 [PMID: 26198300 DOI: 10.1186/s12967-015-0558-8]

72 Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003; 3: 582-591 [PMID: 12894246 DOI: 10.1038/nrc1143]

73 Park SY, Jeong JK, Panupinthu N, Yu S, Lee J, Han JW, Kim JM, Lee JS, Kang J, Park CG, Mills GB, Lee HY. Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MPP-9 expression. Oncogene 2011; 30: 1351-1359 [PMID: 21102517 DOI: 10.1038/ond.2010.517]

74 Wang DS, Dou KF, Li KZ, Song ZS. Enhancement of migration and invasion of hepatoma cells via a Rho GTPase signaling pathway. World J Gastroenterol 2004; 10: 299-302 [PMID: 14716844 DOI: 10.3748/wjg.v10.i2.299]

75 Camps JL, Chang SM, Hsu TC, Freeman MR, Hong SJ, Zhu HE, von Eschenbach AC, Chung LW. Fibroblast-mediated acceleration of human epithelial tumor growth in vivo. Proc Natl Acad Sci USA 1990; 87: 75-79 [PMID: 2299606]

76 Erez N, Truit M, Olson P, Arow ST, Hanahan D. Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. Cancer Cell 2016; 17: 153-167 [PMID: 23038012 DOI: 10.1016/j.ccr.2009.12.041]

77 Albrengues J, Bourget I, Pons C, Butet V, Hofman P, Tartare-Deckert S, Feral CC, Meneguzzi G, Gaggioli C. LIF mediates proinvasive activation of stromal fibroblasts in cancer. Cell Rep 2014; 7: 1664-1678 [PMID: 24587661 DOI: 10.1016/j.celrep.2014.04.036]

78 Satoshy I, Kariyama S, Aiba N, Yashiro M, Tanaka M. Asporin activates coordinated invasion of scirrhous gastric cancer and cancer-associated fibroblasts. Oncogene 2015; 34: 650-660 [PMID: 24441039 DOI: 10.1038/ond.2013.584]

79 Albrengues J, Bertero T, Grasset E, Bonan S, Maedl M, Bourget I, Philippe C, Herraiz Serrano C, Benamar S, Croce O, Sanz-Moreno G. Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts. Nat Commun 2015; 6: 10204 [PMID: 26667266 DOI: 10.1038/ncomms10204]

80 Gopalakrishnan S, Van Embghr BO, Robertson KD. DNA methylation in development and human disease. Mutat Res Rev 2008; 647: 30-38 [PMID: 18778722 DOI: 10.1016/j.mrrmm.2008.08.006]

81 Procopio MG, Laszlo C, Al Labban D, Kim DE, Bordignon P, Jo SH, Goruppi S, Menietti E, Ostano P, Ala U, Provero P, Hoetzenecker W, Neel V, Kilarski WW, Swartz MA, Brisken C, Pollard JW, Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006; 66: 605-612 [PMID: 16423985 DOI: 10.1158/0008-5472.CAN-05-4005]

82 Shirabe K, Mano Y, Muto J, Matono R, Motomura T, Toshima T, Takeishi K, Uchiyama H, Yoshizumi T, Taketomi A, Morita M, Tsujitani S, Sakaguichi Y, Maehara Y. Role of tumor-associated macrophages in the progression of hepatocellular carcinoma. Surg Today 2012; 42: 1-7 [PMID: 22116397 DOI: 10.1007/s00595-011-0058-8]

83 Mano Y, Aishima S, Fujita N, Tanaka Y, Kubo Y, Motomura T, Taketomi A, Shirabe K, Maehara Y, Oda Y. Tumor-associated macrophage promotes tumor progression via STAT3 signaling in hepatocellular carcinoma. Pathobiology 2013; 80: 146-154 [PMID: 23364389 DOI: 10.1159/000346196]

84 Li T, Yang Y, Hua X, Wang G, Liu W, Jia C, Tai Y, Zhang Q, Chen G. Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO. Cancer Lett 2012; 318: 154-161 [PMID: 22182446 DOI: 10.1016/j.canlet.2011.12.020]

85 Cheng JT, Deng YN, Yi HM, Wang GY, Fu BS, Chen WJ, Liu W, Tai Y, Peng YW, Zhang Q. Hepatic carcinoma-associated fibroblasts induce IDO-producing regulatory dendritic cells through IL-6-mediated STAT3 activation. Oncogenesis 2016; 5: e198 [PMID: 26900950 DOI: 10.1038/oncsis.2016.7]

86 Yang L, Pang Y, Moses HL. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010; 31: 220-227 [PMID: 20538542 DOI: 10.1016/j.it.2010.04.002]

87 Chen CH, Kuo LM, Chang Y, Wu W, Goldbach C, Ross MA, Stolz DB, Chen L, Fung JI, Lu L, Qian S. In vivo immune modular activity of hepatic stellate cells in mice. Hepatology 2006; 44: 1171-1181 [PMID: 17058227 DOI: 10.1002/hep.21379]

88 Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman MR, Van Deussen JM, Al Labban D, Kim DE, Bordignon P, Jo SH, Goruppi S, Menietti E, Ostano P, Ala U, Provero P, Hoetzenecker W, Neel V, Kilarski WW, Swartz MA, Brisken C, Pollard JW, Combined CSL and p53 downregulation promotes cancer-associated fibroblasts activation. Nat Cell Biol 2015; 17: 1193-1204 [PMID: 26302407 DOI: 10.1038/ncll.2015.62]

89 Procopio MG, Laszlo C, Dotto GP. CSL-p53: From senescence to CAF activation. Cell Cycle 2016; 15: 485-486 [PMID: 26735629 DOI: 10.1080/15384101.2015.1130691]

90 Childs BG, Duric M, Baker DJ, van Deursen JM. Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nat Med 2015; 21: 1424-1435 [PMID: 26644699 DOI: 10.1038/nm.4000]

91 Sprinzl MF, Galle PR. Immune control in hepatocellular carcinoma development and progression: role of stromal cells. Semin Liver Dis 2014; 34: 376-388 [PMID: 25369300 DOI: 10.1055/s-0034-1394138]

92 Zhang HH, Mei MH, Fei R, Liu F, Wang JH, Liao WJ, Qin LL, Wei L, Chen HS. Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-viral immune responses. J Viral Hepat 2010; 17 Suppl 1: 34-43 [PMID: 20586932 DOI: 10.1111/j.1365-2893.2010.01269.x]

93 Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, Zheng L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med 2009; 206: 1327-1337 [PMID: 19451266 DOI: 10.1084/jem.20082173]
R, Housset C, Rosmorduc O. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. *Hepatology* 2002; 35: 1010-1021 [PMID: 11984751 DOI: 10.1001/jhep.2002.32524]

104 Afelli S, Petrai I, Bertolini C, Parola M, Colombo S, Novo E, Vizzutti F, Anania FA, Milani S, Rombouts K, Laffi G, Pinzani M, Marra F. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. *Hepatology* 2005; 42: 1339-1348 [PMID: 16317688 DOI: 10.1002/hep.20965]

105 Taura K, De Minicis S, Seki E, Hatano E, Iwasako K, Osterreicher CH, Kodama Y, Miura K, Iki U, Uemoto S, Brenner DA. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. *Gastroenterology* 2008; 135: 1729-1738 [PMID: 18823985 DOI: 10.1053/j.gastro.2008.07.065]

106 Ankomna-Set V, Wang Y, Dai Z. Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells. *Hepatology* 2000; 31: 141-148 [PMID: 10163739 DOI: 10.1002/hep.510310122]

107 Gressner AM, Lahme B, Meurer SK, Gressner O, Weikirchen R. Variable expression of cystatin C in cultured trans-differentiating rat hepatic stellate cells. *World J Gastroenterol* 2006; 12: 731-738 [PMID: 16521186]

108 Novo E, Cannito S, Zamara E, Valfrè di Bonzo L, Caligiuri A, Cravanzola C, Compagnone A, Colombo S, Marra F, Pinzani M, Parola M. Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells. *Am J Pathol* 2007; 170: 1942-1953 [PMID: 17525262]

109 Torimura T, Sato M, Ueno T, Kin M, Taiju R, Suzaku K, Hashimoto O, Sugawara H, Tanikawa K. Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. *Hum Pathol* 1998; 29: 986-991 [PMID: 9744316]

110 Jo M, Nishikawa T, Nakajima T, Okada Y, Yamaguchi K, Matsuyoshi H, Yasui K, Minami M, Iwai M, Kagawa K, Itoh Y, Yoshikawa T. Oxidative stress is closely associated with tumor angiogenesis of hepatocellular carcinoma. *J Gastroenterol* 2011; 46: 809-821 [PMID: 21452000 DOI: 10.1007/s00535-011-0392-z]

111 Naylor MS, Stamp GW, Davies BD, Balkwill FR. Expression and activity of MMPs and their regulators in ovarian cancer. *Int J Cancer* 1994; 58: 50-56 [PMID: 8014015]

112 Ding W, You H, Deng H, LeBlanc F, Galicia V, Lu SC, Stiles B, Rountree CB. Epithelial-to-mesenchymal transition of murine liver tumor cells promotes invasion. *Hepatology* 2010; 52: 945-953 [PMID: 20664331 DOI: 10.1002/hep.23374]

113 Elrick LJ, Leel V, Blaylock MG, Duncan L, Drever MR, Strachan G, Charlton KA, Koruth M, Porter AJ, Wright MC. Generation of a monoclonal human single chain antibody fragment to hepatic stellate cells—a potential mechanism for targeting liver anti-fibrotic agents. *Phytother Res* 2012; 26: 344-353 [PMID: 21717514 DOI: 10.1002/ptr.3539]

114 Patella S, Phillips DJ, Tchongue J, de Kretser DM, Sievert W. Follistatin attenuates early liver fibrosis: effects on hepatic stellate cell activation and hepatocyte apoptosis. *Am J Physiol Gastrointest Liver Physiol* 2006; 290: G137-G144 [PMID: 16123203 DOI: 10.1152/ajpgi.00080.2005]

115 Tsai MK, Lin YL, Huang YT. Effects of salvianolic acids on oxidative stress and hepatic fibrosis in rats. *Toxicol Appl Pharmacol* 2010; 242: 155-164 [PMID: 19822164 DOI: 10.1016/j.taap.2009.10.002]

116 Wang X, Ikejima K, Kon K, Arai K, Aoyama T, Okumura K, Abe W, Sato N, Watanabe S. Ursolic acidameliorates hepatic fibrosis in the rat by specific induction of apoptosis in hepatic stellate cells. *J Hepatol* 2011; 55: 379-387 [PMID: 21168456 DOI: 10.1016/j.jhep.2010.09.040]

117 Wright MC, Issa R, Smart DE, Trim N, Murray GI, Primrose JN, Arthur MJ, Jeddale JP, Mann DA. Giltoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. *Gastroenterology* 2001; 121: 685-698 [PMID: 11522753]

118 Shu JC, He YJ, Lv X, Ye GR, Wang LX. Curcumin prevents liver fibrosis by inducing apoptosis and suppressing activation of hepatic stellate cells. *J Gastroenterol Hepatol* 2008; 23: 415-420 [PMID: 19554395 DOI: 10.1017/s1141-009-0347-3]

119 Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. *J Clin Invest* 1998; 101: 1163-1174 [PMID: 9486988 DOI: 10.1172/JCI9992]

120 Fischer R, Schmitt M, Bode JG, Häussinger D. Expression of the peripheral-type benzodiazepine receptor and apoptosis induction in hepatic stellate cells. *Gastroenterology* 2001; 120: 1212-1226 [PMID: 11266385 DOI: 10.1016/gast.2001.23260]

121 Kim JY, Kim KM, Nan JX, Zhao YZ, Park PH, Lee SJ, Sohn DH. Induction of apoptosis by tanshinone I via cytochrome c release in activated hepatic stellate cells. *Pharmacol Toxicol* 2003; 92: 195-200 [PMID: 12753423]

122 Ward SC, Waxman S. Fibroblastic carcinoma: a review with focus on genetics and comparison to other malignant primary liver tumors. *Semin Liver Dis* 2011; 31: 61-70 [PMID: 21344351 DOI: 10.1055/s-0031-1272835]

123 Riehle KJ, Yeh MM, Yu JJ, Kenerson HL, Harris WP, Park JO, Yeung RS. mTORC1 and FGFR1 signaling in fibrolamellar hepatocellular carcinoma. *Mod Pathol* 2015; 28: 103-110 [PMID: 24925055 DOI: 10.1038/modpathol.2014.78]

124 Huang L, Xu AM, Liu S, Liu W, Li TJ. Cancer-associated fibroblasts in digestive tumors. *J Gastroenterol* 2014; 20: 17804-17818 [PMID: 25548479 DOI: 10.3748/wjg.v20.i47.17804]

125 Steinbichler TB, Metzler V, Fritz C, Riechelmann H, Dudas J. Tumor-associated fibroblast-conditioned medium induces CDDP resistance in HCCSC cells. *Oncotarget* 2016; 7: 2508-2518 [PMID: 26497215 DOI: 10.18632/oncotarget.6210]

126 Tanaka K, Miyata H, Sugimura K, Fukuda S, Kanemura T, Yamashita K, Miyazaki Y, Takahashi T, Kurokawa Y, Yamasaki M, Wada H, Nakajima K, Takiguchi S, Mori M, Doki Y. miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts. *Carcinogenesis* 2015; 36: 894-903 [PMID: 26021666 DOI: 10.1093/carcin/bgv067]

127 Poljak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. *Nat Rev Cancer* 2009; 9: 265-273 [PMID: 19262571 DOI: 10.1038/nrc2620]

128 Hawsawi NM, Ghebeh H, Hendrayani SF, Tulbah A, Al-Eid M, Al-Tweigeri T, Ajrami D, Alalaya A, Dermime S, Aboussakha A. Breast carcinoma-associated fibroblasts and their counterparts display neoplastic-specific changes. *Cancer Res* 2008; 68: 2717-2725 [PMID: 18413739 DOI: 10.1158/0008-5472.CAN-08-0192]

129 Amornsupak K, Insawang T, Thuwajit P, O-Chareonrat P, Eccles
Kubo N et al. CAFs in HCC

SA, Thuwajit C. Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells. *BMC Cancer* 2014; 14: 955 [PMID: 25512109 DOI: 10.1186/1471-2407-14-955]

134 Yan H, Guo BY, Zhang S. Cancer-associated fibroblasts attenuate Cisplatin-induced apoptosis in ovarian cancer cells by promoting STAT3 signaling. *Biochem Biophys Res Commun* 2016; 470: 947-954 [PMID: 26826383 DOI: 10.1016/j.bbrc.2016.01.131]

P- Reviewer: Kelleher FC, Cui JF S- Editor: Yu J L- Editor: A E- Editor: Wang CH
